BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
MWN-AI** Summary
BioCorRx Inc. (OTCQB: BICX), based in Anaheim, California, is a biotechnology company dedicated to enhancing the wellness of individuals facing challenges with alcohol and opioid addiction, among other substance use disorders. The company's focus lies in developing and commercializing innovative treatment programs, including medication-assisted therapies.
On December 11, 2025, BioCorRx CEO Lourdes Felix is set to present live at the Life Sciences Virtual Investor Forum, an interactive online event aimed at engaging investors. The presentation, scheduled for 2:30 PM ET, will allow participants to pose real-time questions, and a recording will be made available for those who cannot attend live.
Recent company performance has shown significant signs of growth. BioCorRx reported revenues of $635,224 for Q3 2025, a notable increase from $0 in Q3 2024, alongside a reduced net loss of $808,502 compared to $1.5 million in the previous year. The first half of 2025 featured impressive growth, highlighted by a staggering 3,985% increase in revenue to $313,000, driven by sales of LUCEMYRA® (lofexidine), which also saw a 4,306% rise in revenue in Q2.
Acquired in 2025, LUCEMYRA® is an FDA-approved, non-opioid medication designed to alleviate opioid withdrawal symptoms, thereby strengthening BioCorRx's product portfolio. The company has also garnered increased visibility through a recent research note by Diamond Equity Research, emphasizing the potential of Lucemyra-driven revenue.
Overall, BioCorRx Inc. is strategically positioned to impact addiction treatment with its unique product offerings and innovative approach, making the upcoming investor presentation a key opportunity for stakeholders to engage with the company's vision and progress.
MWN-AI** Analysis
**Market Analysis and Advice on BioCorRx Inc. (OTCQB: BICX)**
As BioCorRx Inc. prepares to present at the Life Sciences Virtual Investor Forum on December 11th, 2025, investors should carefully assess the company’s recent developments and market positioning. The recent financial results indicate a promising trend, with Q3 2025 revenues reaching $635,224, a remarkable turnaround from zero revenues in Q3 2024. Furthermore, the company's significant revenue growth of 3,985% in the first half of 2025, particularly driven by the sales of LUCEMYRA®, suggests robust demand for its innovative treatment programs for substance use disorders.
The acquisition of LUCEMYRA®, a non-opioid medication for mitigating opioid withdrawal symptoms, expands BioCorRx’s commercial portfolio significantly. This FDA-approved product provides a competitive advantage in a critical area of public health, positioning the company favorably within the growing addiction treatment market, which is expected to expand due to rising opioid-related challenges.
Participants in the upcoming investor forum will have the opportunity to engage directly with CEO Lourdes Felix, which can provide valuable insights into future strategies, operational progress, and market outlook. Given that the company's prior financial losses are reducing, with a net loss of $808,502 compared to $1.5 million in Q3 2024, this trend underscores management's ability to pivot and create sustainable revenue streams.
For potential investors, it is crucial to monitor how well BioCorRx can scale its operations and manage its product launches post-acquisition. Following the forum, those holding positions in BICX or contemplating entry should consider potential volatility, given the stock’s OTC status. A diversified entry strategy may be prudent, adjusting for risk, as the company builds its growth narrative. Overall, this opportunity lends itself to a cautiously optimistic outlook, provided that financial and operational advances continue on their current upward trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ANAHEIM, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB:BICX), based in Anaheim, CA, focused on improving the wellness of those struggling with alcohol, opioid, and other addictive disorders, today announced that Lourdes Felix, CEO, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11 th .
DATE : December 11 th
TIME: 2:30 PM ET
LINK: REGISTER HERE
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com .
Recent Company Highlights
- Reported Q3 2025 results with a second straight quarter of meaningful revenue, including $635,224 in Q3 2025 revenue (vs. $0 in Q3 2024) and a reduced net loss of $808,502 (vs. $1.5M in Q3 2024). BioCorRx, Inc.
- Delivered strong 1H 2025 growth driven by LUCEMYRA ® sales, reporting 3,985% revenue growth to $313K for the first half of 2025 and 4,306% growth to $178K in Q2 2025. BioCorRx, Inc.
- Completed/announced the strategic acquisition of LUCEMYRA ® (lofexidine), an FDA-approved, non-opioid medication indicated to mitigate opioid withdrawal symptoms, adding a commercial product to BioCorRx’s portfolio. BioCorRx, Inc.
- Received additional third-party visibility via an updated research note (commissioned by the Company) released by Diamond Equity Research in November 2025, highlighting Lucemyra-driven revenue ramp and business overview.
About BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) is an Anaheim, California-based biotech company focused on improving the lives and wellness of those struggling with alcohol, opioid, and other addictive disorders. Through its subsidiaries, the Company develops and commercializes innovative treatment programs for substance use disorder, including medication-assisted treatment programs.
In 2025, BioCorRx’s pharmaceutical subsidiary acquired LUCEMYRA ® (lofexidine), an FDA-approved, non-opioid medication indicated to mitigate opioid withdrawal symptoms, expanding the Company’s commercial product portfolio.
Important Safety Information
What is LUCEMYRA?
LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder.
Important Safety Information
LUCEMYRA can cause serious side effects, including low blood pressure, slow heart rate, and fainting. Watch for symptoms of low blood pressure or heart rate, including dizziness, lightheadedness, or feeling faint at rest or when quickly standing up; if you experience these symptoms, call your healthcare provider right away and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. Avoid becoming dehydrated or overheated and be careful not to stand up too suddenly from lying or sitting, as these may increase your risk of low blood pressure and fainting. When your treatment is complete, you will need to stop taking LUCEMYRA gradually, or your blood pressure could increase. After a period of not using opioid drugs, you can become more sensitive to the effects of opioids if you start using them again. This may increase your risk of overdose and death. Before taking LUCEMYRA, tell your healthcare provider about all your medical conditions, including if you have low blood pressure, slow heart rate, any heart problems including history of heart attack or a condition called long QT syndrome, liver or kidney problems, or if you drink alcohol. Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding; it is not known if LUCEMYRA can harm your unborn baby or whether LUCEMYRA passes into your breast milk. Especially tell your healthcare provider if you take benzodiazepines, barbiturates, tranquilizers, or sleeping pills, as taking these with LUCEMYRA can cause serious side effects. The most common side effects of LUCEMYRA include low blood pressure or symptoms of low blood pressure such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Click here to see full Prescribing Information .
About Virtual Investor Conferences ®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
BioCorRx Inc.
Lourdes Felix
CEO
(714) 462-4880
info@biocorrx.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
FAQ**
How does BioCorRx Inc (BICX) plan to further enhance revenue growth following the substantial increase reported in Q3 2025, and what strategies are in place to ensure sustained performance moving forward?
Can you elaborate on the impact of LUCEMYRA® sales on BioCorRx Inc's (BICX) overall financial health, especially considering the significant revenue growth reported in the first half of 2025?
What are the key operational challenges BioCorRx Inc (BICX) faces in the commercialization of LUCEMYRA®, and how does the company plan to address them?
How does BioCorRx Inc (BICX) plan to leverage the recent research note from Diamond Equity Research to attract more investors and increase visibility in the market?
**MWN-AI FAQ is based on asking OpenAI questions about BioCorRx Inc (OTC: BICX).
NASDAQ: BICX
BICX Trading
-27.14% G/L:
$0.255 Last:
13,014 Volume:
$0.35 Open:
